M C Genovese

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA 94304, USA
    Ann Rheum Dis 72:1461-8. 2013
  2. doi request reprint A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    Ann Rheum Dis 72:1453-60. 2013
  3. doi request reprint Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure
    Mark C Genovese
    Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA
    J Rheumatol 40:768-80. 2013
  4. doi request reprint Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
    Mark C Genovese
    Department of Rheumatology, Stanford University, Palo Alto, California 94304, USA
    Ann Rheum Dis 72:863-9. 2013
  5. doi request reprint Novel small molecule therapeutics in rheumatoid arthritis
    Victoria Kelly
    Division of Immunology and Rheumatology, Stanford University, 1000 Welch Rd 203, Palo Alto, CA 94304, USA
    Rheumatology (Oxford) 52:1155-62. 2013
  6. doi request reprint Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial
    M C Genovese
    Stanford University, Palo Alto, California 94304, USA
    Arthritis Rheum 65:880-9. 2013
  7. doi request reprint Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA 94304, USA
    J Rheumatol 39:1546-54. 2012
  8. doi request reprint Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study
    Mark C Genovese
    Stanford University, Palo Alto, CA, USA
    J Rheumatol 39:1185-91. 2012
  9. pmc Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
    Sudha Visvanathan
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    Arthritis Res Ther 12:R211. 2010
  10. pmc Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
    Wolfgang Hueber
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, CA 94305, USA
    Arthritis Res Ther 11:R76. 2009

Detail Information

Publications55

  1. doi request reprint Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA 94304, USA
    Ann Rheum Dis 72:1461-8. 2013
    ....
  2. doi request reprint A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    Ann Rheum Dis 72:1453-60. 2013
    ....
  3. doi request reprint Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure
    Mark C Genovese
    Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA
    J Rheumatol 40:768-80. 2013
    ..To assess the longterm safety and efficacy of tocilizumab (TCZ) in patients with moderate to severe rheumatoid arthritis (RA)...
  4. doi request reprint Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
    Mark C Genovese
    Department of Rheumatology, Stanford University, Palo Alto, California 94304, USA
    Ann Rheum Dis 72:863-9. 2013
    ..To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-interleukin-17A antibody, in patients with rheumatoid arthritis (RA)...
  5. doi request reprint Novel small molecule therapeutics in rheumatoid arthritis
    Victoria Kelly
    Division of Immunology and Rheumatology, Stanford University, 1000 Welch Rd 203, Palo Alto, CA 94304, USA
    Rheumatology (Oxford) 52:1155-62. 2013
    ..Ultimately human trials will help us understand the potential risks and benefits of these novel approaches across a number of diseases...
  6. doi request reprint Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial
    M C Genovese
    Stanford University, Palo Alto, California 94304, USA
    Arthritis Rheum 65:880-9. 2013
    ..The aim of this study was to examine the tolerability and efficacy of tabalumab in patients with active rheumatoid arthritis receiving methotrexate...
  7. doi request reprint Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA 94304, USA
    J Rheumatol 39:1546-54. 2012
    ..To evaluate abatacept safety and efficacy over 5 years in patients with rheumatoid arthritis (RA) who had inadequate response to anti-tumor necrosis factor (TNF) therapy in the ATTAIN trial...
  8. doi request reprint Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study
    Mark C Genovese
    Stanford University, Palo Alto, CA, USA
    J Rheumatol 39:1185-91. 2012
    ..To evaluate the effect of golimumab on physical function, general health, and fatigue in patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy...
  9. pmc Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
    Sudha Visvanathan
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    Arthritis Res Ther 12:R211. 2010
    ..The goal of this study was to identify serum markers that are modulated by treatment with golimumab with or without methotrexate (MTX) and are associated with clinical response...
  10. pmc Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
    Wolfgang Hueber
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, CA 94305, USA
    Arthritis Res Ther 11:R76. 2009
    ..Since no clinical or laboratory tests are available to predict response to anti-TNF therapies, great need exists for predictive biomarkers...
  11. ncbi request reprint Biologic therapies in clinical development for the treatment of rheumatoid arthritis
    Mark C Genovese
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road Ste 203, Palo Alto, CA 94304, USA
    J Clin Rheumatol 11:S45-54. 2005
    ..This article reviews a few of the many treatment strategies currently being evaluated, which are hoped to lead to greater benefits and better disease management in the clinical setting...
  12. doi request reprint Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study
    Mark C Genovese
    Division of Rheumatology, Stanford University, Stanford, California 94304, USA
    Arthritis Rheum 58:2652-61. 2008
    ..Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was studied in a first-in-human trial in rheumatoid arthritis (RA) patients receiving concomitant methotrexate (MTX)...
  13. ncbi request reprint A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
    J Rheumatol 32:2345-50. 2005
    ..We evaluated the safety and possible biologic effect of intradermal injections of PVAC in patients with diffuse SSc...
  14. doi request reprint Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug the
    Mark C Genovese
    Division of Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    Arthritis Rheum 58:2968-80. 2008
    ..To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with conventional disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis (RA)...
  15. ncbi request reprint Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    Mark C Genovese
    Stanford University Medical Center, Stanford, Calif, USA
    N Engl J Med 353:1114-23. 2005
    ....
  16. doi request reprint Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
    M C Genovese
    Stanford University School of Medicine, Palo Alto, California, USA
    Ann Rheum Dis 68:1894-7. 2009
    ..To assess the safety of biological disease-modifying antirheumatic drugs (DMARD) in rheumatoid arthritis (RA) patients following rituximab...
  17. ncbi request reprint Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
    M C Genovese
    Stanford University, Division of Immunology and Rheumatology, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Ann Rheum Dis 67:547-54. 2008
    ..To evaluate the safety and efficacy of abatacept during 2 years of the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trial in patients with rheumatoid arthritis...
  18. ncbi request reprint Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
    Mark C Genovese
    Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA 94304, USA
    J Rheumatol 32:1232-42. 2005
    ..To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept...
  19. ncbi request reprint Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
    Mark C Genovese
    Stanford University, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA
    Arthritis Rheum 50:1412-9. 2004
    ..To determine the potential for additive or synergistic effects of combination therapy with the selective anti-tumor necrosis factor alpha agent etanercept and the anti-interleukin-1 agent anakinra...
  20. ncbi request reprint Treatment of rheumatoid arthritis with etanercept
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA
    Rheum Dis Clin North Am 30:311-28, vi-vii. 2004
    ..In addition to its use in RA,etanercept is approved by the U.S. Food and Drug Administration for other rheumatologic conditions, including psoriatic arthritis,ankylosing spondylitis, and juvenile chronic arthritis...
  21. doi request reprint An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
    Arthritis Rheum 63:337-45. 2011
    ..To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies...
  22. doi request reprint A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    J Rheumatol 38:846-54. 2011
    ..To evaluate the efficacy, safety, and tolerability of oral SCIO-469, a p38 MAPK inhibitor that blocks tumor necrosis factor-α, interleukin-1ß, and cyclooxygenase-2 synthesis in patients with active rheumatoid arthritis (RA)...
  23. doi request reprint Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial
    M C Genovese
    Stanford University, Palo Alto, California, USA
    Arthritis Rheum 63:1793-803. 2011
    ..To assess the efficacy, safety, and biologic activity of atacicept in patients with rheumatoid arthritis (RA) in whom the response to treatment with tumor necrosis factor antagonists was inadequate...
  24. pmc Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate
    M C Genovese
    Stanford University, Palo Alto, California 94304, USA
    Arthritis Rheum 63:2854-64. 2011
    ..To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept...
  25. ncbi request reprint Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
    Mark C Genovese
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road 203, Palo Alto, CA 94304, USA
    Arthritis Rheum 46:1443-50. 2002
    ..To compare the clinical and radiographic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 years and to assess the safety of this therapy...
  26. ncbi request reprint Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    J Rheumatol 34:1040-50. 2007
    ..To demonstrate the safety and efficacy of adalimumab for the treatment of active psoriatic arthritis (PsA) in patients with an inadequate response to disease modifying antirheumatic drugs (DMARD)...
  27. doi request reprint LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study
    M C Genovese
    Stanford University, Palo Alto, California 94304, USA
    Arthritis Rheum 62:929-39. 2010
    ....
  28. ncbi request reprint The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
    Karen E Hansen
    Division of Rheumatology, University of Wisconsin, Madison, Wisconsin, USA
    J Rheumatol 31:1098-102. 2004
    ..To describe the degree of clinical benefit in patients with rheumatoid arthritis (RA) who receive infliximab therapy after lack of efficacy with etanercept...
  29. ncbi request reprint A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
    R F van Vollenhoven
    Division of Immunology and Rheumatology, University Medical Center, Stanford, USA
    Lupus 8:181-7. 1999
    ..To determine if dehydroepiandrosterone (DHEA) is beneficial in severe systemic lupus erythematosus (SLE)...
  30. pmc Rules of chemokine receptor association with T cell polarization in vivo
    C H Kim
    Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
    J Clin Invest 108:1331-9. 2001
    ..We conclude that the combinatorial expression of CKRs, which allow tissue- and subset-dependent targeting of effector cells during chemotactic navigation, defines physiologically significant subsets of polarized and nonpolarized T cells...
  31. pmc Unlocking the "PAD" lock on rheumatoid arthritis
    P J Utz
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Ann Rheum Dis 63:330-2. 2004
  32. pmc Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines
    Wolfgang Hueber
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, and Palo Alto VA Health Care System, MC 154R, 3801 Miranda Avenue, Palo Alto, CA 94304, USA
    Ann Rheum Dis 66:712-9. 2007
    ..To identify peripheral blood autoantibody and cytokine profiles that characterise clinically relevant subgroups of patients with early rheumatoid arthritis using arthritis antigen microarrays and a multiplex cytokine assay...
  33. ncbi request reprint Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus
    Eliza F Chakravarty
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    Am J Obstet Gynecol 192:1897-904. 2005
    ..The purpose of this study was to describe the outcomes of a 10-year cohort of pregnancies in patients with systemic lupus erythematosus and to evaluate clinical and laboratory markers for adverse outcomes...
  34. ncbi request reprint Temporal effects of a COX-2-selective NSAID on bone ingrowth
    Stuart B Goodman
    Department of Orthopaedic Surgery, Stanford University Medical Center, Stanford, California 94305 5341, USA
    J Biomed Mater Res A 72:279-87. 2005
    ..This suggests that the effects of COX-2 inhibitors on bone are less profound when the drug is administered for a short period of time...
  35. doi request reprint An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
    Michael E Weinblatt
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:1303-12. 2010
    ..The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy...
  36. ncbi request reprint Autoantigen microarrays for multiplex characterization of autoantibody responses
    William H Robinson
    Division of Immunology and Rheumatology, Department of Medicine, Stanford, California, USA
    Nat Med 8:295-301. 2002
    ..Autoantigen microarrays represent a powerful tool to study the specificity and pathogenesis of autoantibody responses, and to identify and define relevant autoantigens in human autoimmune diseases...
  37. ncbi request reprint Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    Arthritis Rheum 46:1014-8. 2002
    ..To describe the long-term survival, renal condition, and morbidity outcomes in patients who received total lymphoid irradiation (TLI) for the treatment of lupus nephritis...
  38. ncbi request reprint Antigen microarray profiling of autoantibodies in rheumatoid arthritis
    Wolfgang Hueber
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Arthritis Rheum 52:2645-55. 2005
    ....
  39. ncbi request reprint Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis
    Molly D Magnano
    Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    Curr Rheumatol Rep 7:407-15. 2005
    ..Appreciation of the unique interaction between arthritis and common medical co-morbidities may have a significant impact on management and outcomes of RA...
  40. ncbi request reprint A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands
    Molly D Magnano
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California 94304, USA
    J Rheumatol 34:1323-7. 2007
    ..To determine if anti-tumor necrosis factor (TNF) therapy (adalimumab) can safely improve symptoms of erosive/inflammatory osteoarthritis (EOA)...
  41. ncbi request reprint Associations between rheumatoid arthritis and malignancy
    Eliza F Chakravarty
    Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, 203, Palo Alto, CA 94303, USA
    Rheum Dis Clin North Am 30:271-84, vi. 2004
    ....
  42. ncbi request reprint A pilot trial of rituximab in the treatment of patients with dermatomyositis
    Lorinda Chung
    Department of Medicine, Stanford University School of Medicine, 900 Blake Wilbur Dr, Stanford, CA 94305, USA
    Arch Dermatol 143:763-7. 2007
    ..Using quantitative scales, we sought to evaluate the effects of rituximab therapy on muscle strength and skin disease in patients with dermatomyositis...
  43. ncbi request reprint Efficacy results from pivotal clinical trials with abatacept
    A L Rozelle
    Division of Immunology and Rheumatology, Stanford University, Palo Alto, California 94304, USA
    Clin Exp Rheumatol 25:S30-4. 2007
    ....
  44. ncbi request reprint Treatment of rheumatoid arthritis with total lymphoid irradiation: long-term survival
    Z Uhrin
    Stanford University Medical Center, Palo Alto, California 94304, USA
    Arthritis Rheum 44:1525-8. 2001
    ..We would recommend that TLI be used cautiously for patients with refractory RA in whom the benefits outweigh the risks...
  45. pmc Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
    Ricardo T Paniagua
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Clin Invest 116:2633-42. 2006
    ..Imatinib-mediated inhibition of a spectrum of signal transduction pathways and the downstream pathogenic cellular responses may provide a powerful approach to treat RA and other inflammatory diseases...
  46. pmc Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential
    C H Kim
    Laboratory of Immunology and Vascular Biology, Department of Pathology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
    J Clin Invest 107:595-601. 2001
    ..Bonzo may be important in trafficking of effector T cells that mediate type 1 inflammation, making it a potential target for therapeutic modulation of inflammatory diseases...
  47. pmc Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity
    E J Kunkel
    Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA
    J Exp Med 192:761-8. 2000
    ..Selective expression of chemokines by differentiated epithelium may represent an important mechanism for targeting and specialization of immune responses...
  48. ncbi request reprint A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues
    J Pan
    Laboratory of Immunology and Vascular Biology, Departments of Pathology and Surgery, and Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Immunol 165:2943-9. 2000
    ..Consistent with this, MEC attracts eosinophils in addition to memory lymphocyte subsets. These results suggest an important role for MEC in the physiology of extracutaneous epithelial tissues, including diverse mucosal organs...
  49. ncbi request reprint Rheumatic syndromes associated with malignancy
    Eliza Chakravarty
    Department of Medicine, Stanford University, Palo Alto 94304, USA
    Curr Opin Rheumatol 15:35-43. 2003
    ....
  50. ncbi request reprint Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
    Joel M Kremer
    The Center for Rheumatology, LLP, 1367 Washington Avenue, Suite 101, Albany, NY 12206, USA
    Ann Intern Med 137:726-33. 2002
    ..Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate...
  51. ncbi request reprint Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis
    Larry W Moreland
    University of Alabama at Birmingham, Birmingham, AL, USA
    Arthritis Rheum 55:287-93. 2006
    ..To assess the long-term impact of etanercept on fatigue in patients with recent-onset (mean duration 11 months) or established (mean duration 12 years) rheumatoid arthritis (RA)...
  52. ncbi request reprint Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
    ..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms...
  53. ncbi request reprint Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
    ....
  54. ncbi request reprint Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies
    Michael H Schiff
    Denver Arthritis Clinic, University of Colorado, Denver, Colorado 80230, USA
    Drugs Aging 23:167-78. 2006
    ....
  55. pmc Computer-assisted pattern recognition of autoantibody results
    Steven R Binder
    Bio Rad Laboratories, 4000 Alfred Nobel Drive, Hercules, CA 94547, USA
    Clin Diagn Lab Immunol 12:1353-7. 2005
    ..In conclusion, the automated algorithm could identify SLE patterns and may be useful in the identification of patients who would benefit from early referral to a specialist, as well as patients who do not require further evaluation...